Importance Despite recent advances in treatment of severe aortic valve stenosis (AS), AS remains a life-threatening condition with no proven disease-modifying therapy. Low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) (Lp[a]) have been implicated in the pathobiology of AS. The proprotein convertase subtilisin/kexin type 9 inhibitor evolocumab reduces circulating LDL-C concentrations by 50% to 60% and Lp(a) by 20% to 30%. Objective To determine whether evolocumab reduces the risk of AS events in patients with atherosclerotic cardiovascular disease. Interventions Patients were randomized 1:1 to evolocumab or placebo. Design, Setting, and Participants Exploratory analysis of the FOURIER trial, which enrolled 27 & x202f;564 patient...
BackgroundAtherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide...
BACKGROUND: Lipoprotein(a) [Lp(a)] may play a causal role in atherosclerosis. PCSK9 (proprotein conv...
The prevalence of calcific aortic valve disease is increasing with aging of the population. Current ...
Importance: Despite recent advances in treatment of severe aortic valve stenosis (AS), AS remains a ...
Background: Hyperlipidemia has been suggested as a risk factor for stenosis of the aortic valve, but...
Retrospective studies have suggested a beneficial effect of lipid-lowering treatment on the progress...
Aortic stenosis is the most common valvular heart disease among adult subjects in western countries ...
Abstract In this study, we aimed to determine if pretreatment low-density lipoprotein (LDL) levels ...
BACKGROUND: Lipoprotein(a) [Lp(a)] may play a causal role in atherosclerosis. PCSK9 (proprotein conv...
AIMS: To assess the prognostic importance of high-sensitive C reactive protein (hsCRP) in patients w...
BACKGROUND : In the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in...
Aortic valve stenosis (AS) is the most common form of valvular heart disease in the Western world, a...
ObjectivesThe objective of this study was to test the effect of a 3-hydroxy-3-methylglutaryl coenzym...
BACKGROUND : The PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor evolocumab reduced ...
peer reviewedBACKGROUND Evolocumab is a monoclonal antibody that inhibits proprotein convertase subt...
BackgroundAtherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide...
BACKGROUND: Lipoprotein(a) [Lp(a)] may play a causal role in atherosclerosis. PCSK9 (proprotein conv...
The prevalence of calcific aortic valve disease is increasing with aging of the population. Current ...
Importance: Despite recent advances in treatment of severe aortic valve stenosis (AS), AS remains a ...
Background: Hyperlipidemia has been suggested as a risk factor for stenosis of the aortic valve, but...
Retrospective studies have suggested a beneficial effect of lipid-lowering treatment on the progress...
Aortic stenosis is the most common valvular heart disease among adult subjects in western countries ...
Abstract In this study, we aimed to determine if pretreatment low-density lipoprotein (LDL) levels ...
BACKGROUND: Lipoprotein(a) [Lp(a)] may play a causal role in atherosclerosis. PCSK9 (proprotein conv...
AIMS: To assess the prognostic importance of high-sensitive C reactive protein (hsCRP) in patients w...
BACKGROUND : In the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in...
Aortic valve stenosis (AS) is the most common form of valvular heart disease in the Western world, a...
ObjectivesThe objective of this study was to test the effect of a 3-hydroxy-3-methylglutaryl coenzym...
BACKGROUND : The PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor evolocumab reduced ...
peer reviewedBACKGROUND Evolocumab is a monoclonal antibody that inhibits proprotein convertase subt...
BackgroundAtherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide...
BACKGROUND: Lipoprotein(a) [Lp(a)] may play a causal role in atherosclerosis. PCSK9 (proprotein conv...
The prevalence of calcific aortic valve disease is increasing with aging of the population. Current ...